Pathologic Assessment of Response to Chemotherapy in Colorectal Cancer Liver Metastases after Hepatic Resection: Which Method to Use?

Pathology and Oncology Research

Volumn 21, Issue 1, 2015, Pages 173-179

  Dede, K ^a   Salamon, F ^a   Landherr, L ^a   Jakab, F ^a   Bursics, A ^a  

^a UZSOKI HOSPITAL   (Hungary)

Author keywords

colorectal cancer liver metastases; Pathologic response; Preoperative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; HUMAN; LIVER NEOPLASMS; LIVER RESECTION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84930805289     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9803-9     Document Type: Article

References (24)

1. Nordlinger B, Vauthey J-N, Poston G et al (2010) The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 9(4):212–218
2. Chua T. C., Saxena A., Liauw A., et al.: Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases Ann Surg Oncol. 2010 (2):492–501., 17.
3. Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26(11):1830–1835
4. Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20(6):985–92
5. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644–657
6. Dede K, Mersich T, Besznyák I et al (2013) Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assesment. Pathol Oncol Res 19:501–508
7. Scoggins CR, Campbell ML, Landry CS et al (2009) Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 16(1):35–41
8. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment is solid tumors. J Natl Cancer Inst 92:205–216
9. ChunYS, Vauthey JN, Boonsirikamchai P et al. Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal LiverMetastases JAMA. 2 [Epub ahead of print].009 302 (21):2338–2344.
10. Dan G, Blazer III, Yoji K et al (2008) Pathologic response to preoperative chemotherapy: a New outcome End point after resection of hepatic colorectal metastases. J Clin Onc 25(33):5344–5351
11. Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299–304
12. Chang HHI, Leeper WR, Chan G et al (2012) Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 36:570–576
13. Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110(12):2761–2767
14. Maru DM, Kopetz S, Boonsirikamchai P et al (2010) Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34:1287–129
15. Gómez Dorronsoro ML, Vera R, Ortega L, et al. Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy Clin Transl Oncol. [Epub ahead of print].
16. Knijn N, de Ridder JA, Punt CJ et al (2013) Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology 63(2):149–56
17. Ng JKS, Urbanski SJ, Mangat N et al (2008) Colorectal liver metastases contract centripetally with a response to chemotherapy. Cancer 112:362–71
18. Dede K, Láng I, Pörneczi B et al (2013) Preoperative chemotherapy in the surgical treatment of colorectal liver metastases. Magy Seb 66(6):325–30
19. Shindoh J, Loyer EM, Kopetz S et al (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome End point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566–4572
20. Egger ME, Cannon RM, Metzger TL et al (2013) Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg 216:845–56
21. Poultsides GA, Bao F, Servais EL et al (2012) Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis. Predicts outcome. Ann Surg Oncol 19:2797–2804
22. Gruenberger T, Arnold D, Rubbia-Brandt L (2012) Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol 21:309–15
23. Loupakis F, Schirripa M, CaparelloC et al.: Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab Br J Cancer. 2013. [Epub ahead of print].
24. Klinger M, Tamandl D, Eipeldauer S et al (2010) Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 17(8):2059–65